Maculaser develops novel medical technology for treatment of common retinal diseases, including dry Age-related Macular Degeneration.  The core of our innovation is the precise temperature control of the macula during non-damaging laser treatments; a potential game changer in the practise of how major retinal diseases, with over USD 400B direct health care costs, are being treated in the future.
Our innovations allow clinicians to perform previously infeasible laser therapy and potentially help millions of people to retain their vision.

Maculaser Ltd

Org chart

Teams

Offices